anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The phenomenon of near death and dying experiences has been both of popular interest and of scientific speculation. However, the reality of mental perception at the point of death is currently a subjective experience and has not been formally evaluated. While postmortem gene expression, even in humans, has been evaluated, restoration of postmortem brain activity has heretofore only been attempted in animal models, at the molecular and cellular levels. Meanwhile, progress has been made to translate brain activity of living humans into speech and images. This paper proposes two inter-related thought experiments. First, assuming progress and refinement of the technology of translating human brain activity into interpretable speech and images, can an objective analysis of death experiences be obtained by utilizing these technologies on dying humans? Second, can human brain function be revived postmortem and, if so, can the relevant technologies be utilized for communication with (recently) deceased individuals? In this paper, these questions are considered and possible implications explored.
AIMS: Heart failure (HF) and cancer are the leading causes of death worldwide. Epidemiological studies revealed that HF patients are prone to develop cancer. Preclinical studies provided some insights into this connection, but the exact mechanisms remain elusive. In colorectal cancer (CRC), gut microbial dysbiosis is linked to cancer progression and recent studies have shown that HF patients display microbial dysbiosis. This current study focussed on the effects of HF-induced microbial dysbiosis on colonic tumour formation.
METHODS AND RESULTS: C57BL/6J mice were subjected to myocardial infarction (MI), with sham surgery as control. After six weeks faeces were collected, processed for 16 s rRNA sequencing, and pooled for faecal microbiota transplantation. CRC tumour growth was provoked in germ-free mice by treating them with Azoxymethane/Dextran sodium sulphate. The CRC mice were transplanted with faeces from MI or sham mice. MI-induced HF resulted in microbial dysbiosis, characterized by a decreased α-diversity and microbial alterations on the genus level, several of which have been associated with CRC. We then performed faecal microbiota transplantation with faeces from HF mice in CRC mice, which resulted in a higher endoscopic disease score and an increase in the number of tumours in CRC mice.
CONCLUSION: We demonstrated that MI-induced HF contributes to colonic tumour formation by altering the gut microbiota composition, providing a mechanistic explanation for the observed association between HF and increased risk for cancer. Targeting the microbiome may present as a tool to mitigate HF-associated co-morbidities, especially cancer.
Testosterone gel was evaluated in a randomized, five-treatment, single-center, controlled, within-subject study to evaluate the sensitizing potential on healthy volunteers, using a Repeat Insult Patch Test design. Two hundred three (203) subjects completed the study involving Testosterone Gel, a comparator control product, vehicle, and positive and negative controls. All five treatments were applied to the skin separately with an occlusive patch. Each subject received a set of 5 patches, every 48-72 hours for 21 consecutive days. Evaluation of dermal reactions at the application sites were assessed clinically every day at the time of removal of each patch using an established ordinal (6-point) scoring system. Observations at the naïve site during challenge and the pattern of reactivity during induction provided bases for an interpretation of contact sensitizations. Under these conditions there was no evidence of sensitization to testosterone gel, In the cumulative irritancy analysis, testosterone gel was statistically significantly less irritating than the positive control (P<0.001).
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD- 1  with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD- 1 , as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD- 1  antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA- 4  and anti-PD- 1  antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Antenatal education classes were developed to inform expectant mothers about pregnancy, labour and birth and the postpartum period with the aim of improving pregnancy and childbirth experience. They were based, for example, on concepts of Lamaze and Grantly Dick-Read. Studies indicate positive emotional effects on labour and birth outcomes in women who attended antenatal education classes. This includes lower levels of fear of childbirth, lower rates of caesarean birth at the women's request, a higher rate of spontaneous births, and a stronger involvement of the partner, better chances of initiating breastfeeding, a lower likelihood of developing depression symptoms during the postpartum period. There is limited evidence on the link between birth preparation and neonatal outcomes. Considering recent evidence suggesting that antenatal education classes may positively influence maternal and neonatal birth outcomes, we intend to analyse an antenatal education class focusing on a breathing and relaxation technique and assess the impact of such a class on self-efficacy, as well as other maternal and neonatal birth outcomes.
Compounds represented by the general formula (I), (wherein R1? represents a fluorine atom in p-position, a chlorine atom in p-position, a methyl group in p-position or a trifluoromethyl group in p- or m-position, and R2? represents a hydrogen atom, a methyl group, an ethyl group, a 2-hydroxyethyl group or a 3-hydroxypropyl group, provided that R2? represents an ethyl group, a 2-hydroxyethyl group or a 3-hydroxypropyl group when R1? represents a fluorine atom in p-position, a methyl group in p-position or a trifluoromethyl group in p-position), physiologically acceptable salts thereof, process for their preparation, and medicinal composition. These compounds and salts possess an excellent mucous membrane-protecting effect, and are useful for prophylaxis and treatment of peptic ulcer and inflammatory diseases of gastrointestinal tracts.
The canines will be retracted by extending short silver elastomeric chains between the power arms in the canine brackets and the TADs. The applied force will be checked and adjusted to 150 g.
1-(2-Hydroxy-2-indanyl)propylamine is prepd. from 2-indanone cyanhydrin in which the hydroxyl group is protected by a vinyl alkyl ether group of formula RO.CH:CH2 (where R is 1-6C alkyl), by addition of an ethylmagnesium halide hydrolysing the reaction product and hydrogenating the imine to an amine group and removing the protective group. The product, an anorectic and lipolytic agent, is made in 55-60% yield without any increase in cost of raw materials. Typically, the cyanhydrin is protected by reaction with vinyl ethyl ether in THF, the solvent is evapd. and the residue in toluene is treated with ethylmagnesium bromide in THF, and the product hydrolysed. The imine in toluene is hydrolysed with LiAlH4 and converted into the hydrochloride (yield 57% of overall).
BACKGROUND: Par-3 Family Cell Polarity Regulator (PARD3) is a cellular protein essential for asymmetric cell division and polarized growth. This study aimed to study the role of PARD3 in hepatic tumorigenesis.
METHODS: The essential role of PARD3 in mediating hepatic tumorigenesis was assessed in diet-induced spontaneous liver tumour and syngeneic tumour models. The mechanism of PARD3 was delineated by bulk and single-cell RNA sequencing. The clinical significance of PARD3 was identified by tissue array analysis.
RESULTS: PARD3 was overexpressed in tumour tissues and PARD3 overexpression was positively correlated with high tumour stage as well as the poor prognosis in patients. In models of spontaneous liver cancer induced by choline-deficient, amino acid-defined (CDAA) and methionine-choline-deficient (MCD) diets, upregulation of PARD3 was induced specifically at the tumorigenesis stage rather than other early stages of liver disease progression. Site-directed knockout of PARD3 using an adeno-associated virus 8 (AAV8)-delivered CRISPR/Cas9 single-guide RNA (sgRNA) plasmid blocked hepatic tumorigenesis, while PARD3 overexpression accelerated liver tumour progression. In particular, single-cell sequencing analysis suggested that PARD3 was enriched in primitive tumour cells and its overexpression enhanced tumour-initiating cell (TICs). Overexpression of PARD3 maintained the self-renewal ability of the CD133+ TIC population within hepatocellular carcinoma (HCC) cells and promoted the in vitro and in vivo tumorigenicity of CD133+ TICs. Transcriptome analysis revealed that Sonic Hedgehog (SHH) signalling was activated in PARD3-overexpressing CD133+ TICs. Mechanistically, PARD3 interacted with aPKC to further activate SHH signalling and downstream stemness-related genes. Suppression of SHH signalling and aPKC expression attenuated the in vitro and in vivo tumorigenicity of PARD3-overexpressing CD133+ TICs. Tissue array analysis revealed that PARD3 expression was positively associated with the phosphorylation of aPKC, SOX2 and Gli1 and that the combination of these markers could be used to stratify HCC patients into two clusters with different clinicopathological characteristics and overall survival prognoses. The natural compound berberine was selected as a potent suppressor of PARD3 expression and could be used as a preventive agent for liver cancer that completely blocks diet-induced hepatic tumorigenesis in a PARD3-dependent manner.
CONCLUSION: This study revealed PARD3 as a potential preventive target of liver tumorigenesis via TIC regulation.
In one aspect of the disclosed technology, the system includes a data collection marketplace. In some implementations, marketplace users may request publication of a data collection to the data collection marketplace. Registry users may browse the data collection marketplace and subscribe to a data collection request. In certain embodiments, patient data collected by a registry user is provided to the data collection marketplace. The patient data responsive to data collection requests, in certain embodiments, is made available to the marketplace users that published these data collection requests. Marketplace users may use the data for a variety of purposes, including clinical studies and market research.
PURPOSE:To provide a hepatic function improving and hypotensive agent having high safety and the activity to decrease the GOT and GPT values in the serum effectively and the hypotensive activity, by using living or dead cells of microorganisms belonging to Streptococcus genus. CONSTITUTION:The objective agent for improving hepatic function and a hypotensor contains the living or dead cells of microorganisms belonging to Streptococcus genus (e.g. Streptococcus faecalis, faecium, bovis, etc.) as an active component. The microorganism is effective to lower the GOT and GPT values in serum as an agent for improving hepatic function and suppresses the blood pressure from the state of hypertension to the normal state as a hypotensor. It is useful as a remedy and preventive for myocardial infarction, cerebral apoplexy, arteriosclerosis, acute hepatitis, chronic hepatitis, hepatocirrhosis, etc. It is administered by oral administration, intravenous injection, etc., at a dose of 10<7>-10<14> cells per kg body weight.
Breast-conserving therapy (BCT) is a breast cancer treatment using breast conservative surgery(BCS) with lymph node dissection and with or without following by radiotherapy(RT). (Morrow,2004). Results of BCTs demonstrate high rates of local tumor control with satisfactory cosmetic results. (Morrow,2004) Nowadays, the local treatment of breast cancer has slowly accepted from radical mastectomy with lymph node dissection to (BCT) in the last 100 years. (Morrow,2004) After surgical intervention for breast cancer carcinoma, the most frequent morbilities are lymphedema of the unilateral upper extremity and shoulder dysfunction. (Wingate L,1985; Grube, 2004)From the perspective of the Institute of Medicine's(IOM), the outcome measures shifts from the impairment-based measures to functional limitation measures. (Jette AM,1995) Base on the third element in Donabedian's framework of quality of physical therapy care, the determination of outcomes in terms of death, morbidity, disability, or quality of life. (Jette AM,1995)Although shoulder active range-of-motion exercises could start at the day right after any type or level of lymph node dissections for breast cancer patients, (Staradub VL, 2004;Wingate L,1985) in my literature review results, no functional evaluation questionnaires that was sensitive enough to detect the disabilities resulting from lymph node dissections at post BCS 2 days. So we revise 8 disability items from SPADI into Chinese to develop a simple self-completion questionnaire for the assessment of restriction in daily activities resulting from breast conservative surgery.

The purpose of this study was to validate the score obtained from this questionnaire by testing restriction of shoulder active flexion and abduction on examination at post BCS 2 days correlates with disability score.
The recommended dosage of REZLIDHIA is 150 mg taken orally twice daily until disease progression or unacceptable toxicity. Administer REZLIDHIA capsules orally about the same time each day. Do not administer 2 doses within 8 hours. Take on an empty stomach at least 1 hour before or 2 hours after a meal [see Clinical Pharmacology (12.3)]. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.

Swallow REZLIDHIA capsules whole. Do not break, open, or chew the capsules. If a dose of REZLIDHIA is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of REZLIDHIA is missed or not taken at the usual time, administer the dose as soon as possible and at least 8 hours prior to the next scheduled dose. Return to the normal schedule the following day.
Individuals will not be prompted to practice skills. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
FIELD: food industry and technology. SUBSTANCE: invention claims method for separation and extraction of protein and isoflavones from soybean material containing thereof. Method involves preparing the purified extract of soybean material that interacts with strong-base anion- exchange resin based on quaternary ammonium groups. From soybean protein extract purified from isoflavones and isolated from anion-exchange resin isoflavone-free soybean protein material is extracted. After isolation of isoflavone-free soybean protein extract from anion-exchange resin isoflavones are isolated and extracted from anion-exchange resin. Isolated isoflavone glycosides and conjugated isoflavone glycosides can be converted to form of their corresponding aglycone isoflavones. Method provides the complete separation and extraction of proteins and isoflavones from soybean protein material containing thereof. EFFECT: improved separation and extraction method. 36 cl, 2 deg, 2 tbl
The present invention relates to novel 23-oxo (keto) and 23-imino derivatives of LL-F28249 alpha , beta , gamma , delta , epsilon , zeta , theta , i and lambda compounds. These LL-F28249 compounds (collectively) are isolates from the fermentation broth of Streptomyces cyaneogriseus subspecies noncyanogenus having deposit accession number NRRL 15773. The present 23-oxo compounds are prepared by selectively oxidizing suitably protected 23-hydroxy compounds of LL-F28249 components using oxidizing agents. Subsequently, the 23-oxo compounds are converted to the 23-imino compounds. These novel compounds have potent anthelmintic, insecticidal, ectoparasiticidal, nematicidal and acaricidal activity. Compositions containing these 23-oxo and 23-imino derivatives of LL-F28249 also are described herein.
Obsessive-Compulsive Disorder (OCD) often onsets in childhood and, if not effectively treated, can lead to lifelong illness and poor functional outcomes. Cognitive behavioral therapy (CBT) with exposure and response prevention (EXRP) is the gold-standard, first-line treatment for children with OCD. However, as many as 40% of pediatric patients treated fail to remit. Based on the extant literature and our preliminary data showing that cognitive control functions are altered in children with OCD, this study is designed to test the hypothesis that cognitive control training (CT) should engage the Cognitive System to prime and augment EXRP response. A 2-year proof of concept study will be conducted to determine if CT enhances cognitive control behavioral performance (target engagement) in 60 children (8-12 years old) with OCD sampled from the general community and affiliated clinics. Children will receive 4 weeks of an at-home computerized cognitive training program (AKL-T01; FDA-approved for pediatric ADHD) delivered on iPad (25 minutes/day, 5 days/week). Styled as a child-friendly video game, AKL-T01 CT taps focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes. Children will complete the NIH Toolbox prior to, mid (2-weeks), and post-CT (4-weeks). Cognitive control behavior will be indexed by NIH Toolbox Cognitive Function Composite. Participants will complete MRI scans pre- and post-CT and then be offered a 12-week course of gold-standard CBT EXRP (or community referrals) after CT. Resting state functional connectivity between task control networks and the Default Mode Network will be explored as a potential mechanism of action.
PURPOSE: An external use skin composition containing dimethyl sulfonyl methane(DMSO2) and alum is provided to treat allergy and inflammation and to promote blood circulation. CONSTITUTION: An external use skin composition contains 10-90% of methyl sulfonic methane and 10-90% of alum. The composition contains 10-90% of a mixture of methyl sulfonic methane and alum and 10-95% of solvent. The solvent includes one or more kinds of water among distilled water, anionic water, tree sap, wastewater prepared after making bean curd, and deep water. The external use skin composition is manufactured in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing oil, emulsion foundation, wax foundation, or spray. The composition is used for skin whitening, anti-wrinkling, and moisturization.
In response to the large numbers of senior center clients who suffer from untreated depression, we have partnered with the NYC Department for the Aging (DFTA) to develop SMART-MH, a community care model that can be embedded in senior centers to improve recognition, referral, and adherence to depression treatment. The investigators also developed and tested Engage, a stepped-care therapy streamlined to use "reward exposure" as its principal intervention based on the assumption that dysfunction of the reward networks is central to the pathogenesis of depression. With senior center partners and a mobile technology team, the investigators redesigned Engage-M so that it can be used in a group format by licensed clinical social workers (LCSWs) of Senior Centers. Mobile technology provides probes for client adherence and offers to therapists easy to review summary records of mood, activity, and social interaction that can be used to target their sessions. The investigators have integrated SMART-MH and Engage-M into a comprehensive community care model "Reaching and Engaging Depressed Senior Center Clients" (REDS).

The specific aims of this developmental project are to: 1. Finalize the REDS protocol and assess feasibility of training; 2. Prepare an Operations' Manual; 3. Examine reach, feasibility, and acceptability of REDS; 4. Examine engagement of behavioral targets and preliminary effectiveness; and 5. Collect information on REDS cost, barriers to implementation, and potential savings in health care utilization.

The investigators will randomly assign four senior centers to offer either Engage-M (N=40), the treatment offered by REDS (1 individual and 8 weekly group sessions) or 8 group sessions "Wellness in Mind and Body" plus mental health referral (W-MH; N=20). The participants will have clinically significant depressive symptoms (PHQ-9\>10) and will be older and middle-aged adults (55+); 12.6% of the NYC senior center clients are aged 55-65 years. Clients will be identified by senior center staff trained in SMART-MH strategies. The investigators will offer additional training to staff of all centers on SMART-MH outreach, depression screening, and treatment engagement. The investigators will train and provide weekly supervision to 2 or more LCSWs per center of the two centers assigned to Engage-M. The investigators will not offer training or supervision to senior center staff leading the groups of W-MH but will provide oversight so that clients receive mental health referrals and are encouraged to attend weekly Wellness group meetings.
BACKGROUND: In contrast to proteinuric chronic kidney disease (CKD), the relative cardioprotective benefits of antihypertensive medications in nonproteinuric CKD are unknown. We examined long-term cardiovascular outcomes and mortality in patients with nonproteinuric CKD treated with renin-angiotensin system inhibitors (RASIs) versus other antihypertensive medications.
METHODS: Among participants of the CRIC study (Chronic Renal Insufficiency Cohort) without proteinuria, we used intention-to-treat analyses with inverse probability of treatment weighting and Cox proportional hazards modeling to determine the association of RASIs versus other antihypertensive medications with a composite cardiovascular outcome (myocardial infarction, stroke, heart failure hospitalization, and death) and mortality. Secondary analyses included per-protocol analyses accounting for continuous adherence and time-updated analyses accounting for the proportion of time using RASIs during follow-up.
RESULTS: A total of 2806 participants met the inclusion criteria. In the intention-to-treat analyses, RASIs versus other antihypertensive medications were not associated with an appreciable difference in cardiovascular events (adjusted hazard ratio [aHR], 0.94 [95% CI, 0.80-1.11]) or mortality (aHR, 1.06 [95% CI, 0.88-1.28]). In the per-protocol analyses, RASIs were associated with a lower risk of adverse cardiovascular events (aHR, 0.78 [95% CI, 0.63-0.97]) and mortality (aHR, 0.64 [95% CI, 0.48-0.85]). Similarly, in the time-updated analyses, a higher proportion of RASI use over time was associated with a lower mortality risk (aHR, 0.33 [95% CI, 0.14-0.86]).
CONCLUSIONS: Among individuals with nonproteinuric CKD, after accounting for time-updated use, RASIs are associated with fewer cardiovascular events and a lower mortality risk compared with other antihypertensive medications. Patients with nonproteinuric CKD may benefit from prioritizing RASIs for hypertension management.
FIELD: medicine. SUBSTANCE: product: cobalt-iron-containing polyacrylic acid used as hemostatic showing local action and high antimicrobial activity. Proposed agent as 1% aqueous solutions at contact with native blood forms immediately the dense stable clot. Its action is similar with that of feracryl. Bacteriostatic activity of cobacryl exceeds significantly that of feracryl with regard to some strains. EFFECT: enhanced effectiveness of complex